Pharmaceuticals

Aimovig Market Expansion Forecast Reaching $30.17 Billion By 2030 At 5.3% CAGR

May 5, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Aimovig Market Over The 2026–2030 Period?

Historical growth stemmed from a significant occurrence of migraines, the restricted efficacy of conventional treatments, the authorization of CGRP inhibitors, neurologists embracing these treatments, and patients seeking proactive solutions.

Anticipated market expansion in the upcoming period is attributable to an increase in chronic migraine diagnoses, broader insurance coverage, greater acceptance of biologic drugs, enhanced patient outcome data, and a rise in neurology specialist consultations.

Key developments anticipated during the forecast timeframe include the increasing utilization of CGRP-targeted therapies, a heightened emphasis on preventive migraine treatment, a transition from acute to long-term migraine management approaches, expanded application of biologic therapies, and the wider reach of specialty pharmacy distribution networks.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19866&type=smp

Which Strong Drivers Are Impacting The Aimovig Market Growth?

The aimovig market is projected to grow due to the increasing occurrence of migraine disorders. Migraine is a complex neurological condition characterized by recurring headaches, often accompanied by symptoms like nausea and sensitivity to light and sound. The rise in migraine cases stems from various factors, including evolving lifestyles, heightened stress, genetic predispositions, hormonal changes (especially in women), and improved diagnostic understanding. Aimovig, the initial FDA-approved CGRP receptor blocker, provides a primary, targeted, and preventive solution for migraine patients, addressing their unmet needs. This innovative migraine management platform utilizes advanced AI algorithms to monitor, analyze, and forecast migraine triggers, offering customized advice for prevention, symptom alleviation, and real-time management through data-driven insights. Ultimately, it assists patients in decreasing the frequency, intensity, and duration of their attacks, thereby enhancing their overall quality of life. For instance, in March 2024, the House of Commons Library, a UK government agency, reported that approximately 10 million individuals in the UK live with migraine. Consequently, the growing prevalence of migraine disorders is a key driver for the aimovig market.

Aimovig Market Driver: Impact Of Rising Healthcare Spending On The Aimovig Market

The aimovig market is anticipated to expand with the projected increase in healthcare spending. Healthcare spending encompasses all financial resources directed by individuals, governments, private insurers, and other entities towards healthcare services and products. This rise is attributed to an aging population, advancements in medical technology, the growing prevalence of chronic illnesses, and a heightened demand for healthcare services. Healthcare expenditure supports Aimovig by stimulating investment in new treatments, broadening patient access through insurance, financing ongoing research and development for improved therapeutic outcomes, and advancing public health initiatives that increase awareness and foster broader adoption of migraine prevention therapies. For example, in May 2024, the Office for National Statistics, a UK government department, indicated that UK healthcare spending between 2022 and 2023 climbed by 5.6%, a significant increase compared to the 0.9% growth seen in 2022. The total UK healthcare expenditure reached approximately $317.63 billion (£292 billion) in 2023. Thus, the growth of the aimovig market is propelled by increasing healthcare spending.

How Are Different Segments Classified In The Aimovig Market Segment Analysis?

The aimovig market covered in this report is segmented –

1) By Clinical Indication: Migraine, Cluster Headache, Other Headache Disorders

2) By Distribution Channel: Hospital And Clinics, Retail And Specialty Pharmacies

3) By End User: Adult, Geriatric

Who Are The Companies Driving Activity In The Aimovig Market?

Major companies operating in the aimovig market are Novartis AG, Amgen Inc.

Get The Full Aimovig Market Report:

https://www.thebusinessresearchcompany.com/report/aimovig-global-market-report

Which Region Represents The Largest Share Of The Aimovig Market?

North America was the largest region in the aimovig market in 2025. The regions covered in the aimovig market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Aimovig Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/aimovig-global-market-report

Browse Through More Reports Similar to the Global Aimovig Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Investments Market Report 2026

https://www.thebusinessresearchcompany.com/report/investments-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795